Biotech Enters the Era of Profitability? A Closer Look at the Changing Landscape

In recent years, the biotech industry has been characterized by long periods of investment and development, with profitability often being elusive for many companies. However, a new wave of financial reports suggests a shift in the landscape, as several biotech firms have started to show signs of reducing losses or even turning a profit. This article explores the emerging trend of profitability in the biotech sector and examines the strategies employed by successful companies to achieve this milestone.

Diversified Profitability Models:

Traditionally, biotech companies have relied on blockbuster products to generate commercial revenues and drive overall growth. However, due to the complex and lengthy R&D processes, substantial capital investments, and high risks involved in the development of biopharmaceutical products, solely relying on product commercialization for profitability has become a formidable challenge for many biotech firms. To overcome this hurdle, some companies have embraced alternative revenue models, such as product licensing and partnerships.

Case Study 1: Henlius' Success with Core Product Commercialization

Henlius became the first Hong Kong biotech company to achieve profitability through product sales. In 2023, the company reported an annual revenue of approximately 5.395 billion Chinese yuan, a 67.8% year-on-year increase, and a net profit of 546 million Chinese yuan. Henlius' profitability was primarily driven by the continuous growth in sales of its core products, Hanquyou® (trastuzumab) and HyaMabs® (slutuximab). The sales revenue of these two products accounted for 2.737 billion yuan and 1.119 billion yuan, respectively, in 2023. Hanquyou® demonstrated robust growth, with a domestic market share increase and sales revenue of approximately 2.644 billion yuan, a 56.1% year-on-year increase. Additionally, HyaMabs®, as the first approved PD-1 monoclonal antibody for the first-line treatment of small-cell lung cancer, achieved remarkable sales growth after its market debut, contributing 1.119 billion yuan to Henlius' revenue in 2023, surpassing the 1 billion yuan mark.

Case Study 2: Harbour BioMed ' Success through Licensing Deals

Harbour BioMed ' profitability model differs from Henlius' approach. In 2023, Harbour BioMed reported a total revenue of 89.502 million USD, a year-on-year increase of approximately 120%, and a net profit of 22.763 million USD. Harbour BioMed , which does not have any commercialized products yet, achieved profitability primarily through revenue generated from licensing deals. The company entered into licensing and collaboration agreements with prominent partners such as Pfizer, Cullinan Oncology, and Corning Pharma. These partnerships resulted in significant upfront payments and milestone payments, which contributed to Harbour BioMed ' positive financial performance. By strategically controlling costs, reducing administrative expenses, and optimizing research and development expenditures, the company achieved its first annual profit milestone since its listing on the Hong Kong Stock Exchange in 2020.

Case Study 3: Akeso Biopharma's Convergence of Single Product Sales and Licensing

Akeso Biopharma took a dual approach to profitability. In 2023, the company reported a total revenue of 4.526 billion yuan, a remarkable 440% year-on-year growth, and a net profit of 1.942 billion yuan. Akeso Biopharma's success can be attributed to a combination of revenue streams derived from single product sales and licensing agreements. The company generated substantial revenue from the licensing of its globally innovative dual-specific antibody, YidaFang® (ivosidenib, PD-1/VEGF dual-specific antibody), particularly through a licensing agreement with Summit for certain overseas market rights. Additionally, the company achieved significant growth in product sales, with 2023 sales reaching 1.631 billion yuan, a 48% year-on-year increase.

The biotech industry is witnessing a transformative period, with several companies breaking the profitability barrier. While the traditional model of relying solely on blockbuster products for revenue generation still holds significance, the emergence of diversified models, such as licensing deals and strategic partnerships, is reshaping the landscape. Biotech companies are increasingly adopting a combination of approaches to achieve financial success. As the biotech sector continues to evolve, these innovative strategies will play a vital role in driving profitability and sustaining long-term growth in the industry.